Clinical Supply, Gene Therapy and Immune Response

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Clinical Supply

Gene Therapy

Immune Response

CSL makes $4bn+ move in mRNA vaccines with Arcturus deal

pharmaphorum

NOVEMBER 2, 2022

The promise in the self-assembling RNA technology lies in its potential to achieve a strong immune response using a lower dose of antigen than the current generation of mRNA shots, although it is generally a larger molecule and may be more challenging to deliver.

Vaccination

Vaccination Vaccine Immune Response Gene Therapy

A supply chain to match the changing face of science

Drug Discovery World

NOVEMBER 3, 2022

Ten years ago, cell and gene therapy (CGT) was really finding its feet as success stories such as that of Emily Whitehead began to hit the news. They also do not have the potential of causing a severe immune response if they are administered to the wrong patient. The catalysts . References .

Gene Therapy

Gene Therapy Production Development Business Development

Clinical Research Informer

CSL makes $4bn+ move in mRNA vaccines with Arcturus deal

A supply chain to match the changing face of science

Stay Connected